Health Canada is currently scrutinizing a significant revamp of pharmaceutical advertising standards proposed by the Pharmaceutical Advertising Advisory Board (PAAB).
The primary focus is on modernizing the approach to Real-World Evidence (RWE). The draft RWE guidance document, developed through extensive industry collaboration, outlines a transparent and evidence-based framework for including RWE in health professional-targeted advertising.
Proposed changes aim to broaden permissible RWE findings, with stringent criteria for evidence quality and relevance. The overhaul also extends to clinical trial criteria, allowing subjective endpoints and relaxing formulation matching requirements for trials from other jurisdictions.
For a detailed breakdown, explore the tabulated text comparison of the current vs. proposed Code sections.
